Rheumatologists do prescribe pain medication, but their approach to pain looks different from what many patients expect walking into the clinic. The specialty’s primary strategy centers on treating the underlying disease with drugs that slow or halt joint destruction, and pain relief often follows from that. When it doesn’t, rheumatologists reach for a range of analgesics, from anti-inflammatories and corticosteroids to certain antidepressants and, in some cases, opioids. The tension between controlling disease and controlling pain is one of the defining challenges in modern rheumatology, and the gap between the two is wider than many guidelines acknowledge.
Disease Control Comes First, Pain Management Second
The foundation of treatment for inflammatory conditions like rheumatoid arthritis is a class of drugs called disease-modifying antirheumatic drugs, or DMARDs. These medications target the immune dysfunction driving joint inflammation, and when they work well, pain drops substantially as a side effect of disease control. A narrative review of pain management strategies in rheumatoid arthritis found that DMARDs are the fundamental basis of treatment because the main mechanism of pain in the condition is inflammation.1PubMed Central. Pharmacological pain management in patients with rheumatoid arthritis: a narrative literature review But here’s the problem: a significant number of patients continue to have pain despite what clinicians consider optimal disease treatment.
This creates a peculiar situation. The most recent American College of Rheumatology guideline for rheumatoid arthritis focuses almost entirely on DMARD selection and disease activity targets, with pain scarcely mentioned.1PubMed Central. Pharmacological pain management in patients with rheumatoid arthritis: a narrative literature review So while rheumatologists certainly can and do prescribe pain medication, the formal guidance that shapes their practice prioritizes disease suppression. Pain management often ends up being handled on a case-by-case basis rather than following a structured protocol.
NSAIDs and Corticosteroids Are the Workhorses
The pain medications most commonly associated with rheumatology are nonsteroidal anti-inflammatory drugs and corticosteroids. NSAIDs like ibuprofen, naproxen, and celecoxib reduce both pain and inflammation, making them a natural fit for inflammatory joint diseases. Rheumatologists prescribe them routinely, sometimes as a bridge while waiting for DMARDs to take effect and sometimes for ongoing flare management.
Corticosteroids occupy a more complicated role. They work fast, which makes them invaluable during disease flares when patients need rapid relief. Modern guidelines for rheumatoid arthritis, lupus, and polymyalgia rheumatica recommend short-term glucocorticoid use as bridging therapy at the lowest effective dose, often alongside disease-modifying drugs.2The Lancet Rheumatology. Glucocorticoid treatment in patients with inflammatory rheumatic diseases: current practice and open questions Glucocorticoids are considered essential for managing life-threatening autoimmune diseases and a cornerstone in many inflammatory conditions because of their swift onset of action.3PubMed Central. The dichotomy of glucocorticosteroid treatment in immune-inflammatory rheumatic diseases: an evidence-based perspective and insights from clinical practice The catch is that long-term steroid use carries serious risks, including bone loss, weight gain, and metabolic problems. Most rheumatologists view steroids as a tool to be used briefly and tapered, not a long-term pain solution.
The Problem of Pain That Persists After Remission
One of the more frustrating realities in rheumatology is that controlling the disease doesn’t always eliminate the pain. Residual pain is now recognized as a major unmet medical need in rheumatoid arthritis, decreasing quality of life even after patients achieve remission or low disease activity.4Reumatologia. The problem of residual pain in the assessment of rheumatoid arthritis activity In one study of patients who had achieved sustained clinical and ultrasound-confirmed remission, nearly half still reported unacceptable levels of pain.5PubMed Central. Residual pain and fatigue are affected by disease perception in rheumatoid arthritis in sustained clinical and ultrasound remission A systematic review looking at patients in remission or low disease activity found that about one in eight patients meeting strict remission criteria still had clinically significant pain scores.6Modern Rheumatology. Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review
This residual pain doesn’t respond well to more disease-modifying drugs, because the inflammation is already controlled. It represents a different kind of pain, often driven by changes in how the nervous system processes pain signals rather than by ongoing joint damage. For these patients, the rheumatologist needs to shift from an anti-inflammatory approach to something more targeted at pain processing itself.
When the Pain Isn’t Inflammatory
Rheumatologists increasingly recognize that not all pain in their patients comes from active inflammation. Central sensitization and conditions like fibromyalgia can amplify pain signals even when joints look quiet on imaging and blood work. Distinguishing inflammatory pain from non-inflammatory pain changes the treatment strategy entirely.
For non-inflammatory or “nociplastic” pain, standard analgesics may not be the right tool. UK guidelines explicitly recommend against using conventional painkillers for chronic primary pain that is out of proportion with the underlying disease. Instead, they recommend antidepressants with established pain-modifying properties, with amitriptyline and duloxetine as first-line options because of their effects on pain-processing pathways in the brain and spinal cord.7PubMed Central. How to Distinguish Non-Inflammatory from Inflammatory Pain in RA? For fibromyalgia specifically, a pharmacological review found that amitriptyline, serotonin-noradrenaline reuptake inhibitors like duloxetine, and gabapentinoids like pregabalin are the most commonly used agents, with duloxetine and its class being the most widely recommended.8PubMed. How to treat chronic pain in rheumatic and musculoskeletal diseases (RMDs) – A pharmacological review
So yes, a rheumatologist may prescribe you an antidepressant for your joint pain, and that’s not because they think the pain is in your head. These drugs genuinely modify how the nervous system handles pain signals. If you’re prescribed duloxetine or amitriptyline for a rheumatic condition, the intent is analgesic, not psychiatric.
Opioids and Rheumatology’s Complicated Relationship With Them
Opioids are where the conversation gets thornier. Rheumatologists do prescribe them, though the specialty has been moving away from routine opioid use in line with broader trends in medicine. A large U.S. study of over 4,000 rheumatologists found striking variability: in the average rheumatologist’s practice, about 40% of rheumatoid arthritis patients used prescription opioids regularly. In almost half of those patients, at least some of the opioid prescriptions came directly from a rheumatologist, and about 14% had opioids prescribed concurrently by more than one physician.9PubMed. Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States
Trends over time show that opioid use among rheumatic disease patients generally rose through the late 2010s before plateauing or declining. For rheumatoid arthritis specifically, the number of prevalent opioid users increased until around 2019 and then stabilized or dropped. Fibromyalgia stood out as an exception, with opioid use continuing to climb through 2021.10Rheumatology. Trends for opioid prescribing and the impact of the COVID-19 pandemic in patients with rheumatic and musculoskeletal diseases between 2006 and 2021
Regulatory pressure has reshaped how rheumatologists handle opioid prescriptions. A study from an academic rheumatology practice found that at baseline, only 40% of patients on opioids had a signed opioid agreement (required by state guidelines or law), only a quarter had a recent urine drug screen, and roughly a quarter had a concurrent benzodiazepine prescription, a combination that raises overdose risk significantly.11PubMed. Targeted Program in an Academic Rheumatology Practice to Improve Compliance With Opioid Prescribing Guidelines for the Treatment of Chronic Pain Programs targeting compliance with opioid prescribing guidelines have pushed many rheumatology practices toward more structured oversight, including agreements, urine monitoring, and careful co-prescribing review. The era of casual opioid prescribing in rheumatology is largely over, though the medications haven’t disappeared entirely. For patients with severe, refractory pain, weak opioids like tramadol remain part of the conversation.
Topical Treatments and Joint Injections
Not everything a rheumatologist prescribes for pain comes in pill form. Topical NSAIDs, applied directly over a painful joint, are an increasingly favored option. International guidelines recommend topical NSAIDs on par with or ahead of oral NSAIDs for knee and hand osteoarthritis, and as the first-line choice in people over 75 because they deliver pain relief with far fewer systemic side effects.12PubMed. Consensus recommendations for managing osteoarthritic pain with topical NSAIDs in Asia-Pacific The evidence from randomized controlled trials suggests that topical NSAIDs cause no more adverse events than placebo gels, which is a meaningful advantage over oral versions that can affect the stomach, kidneys, and cardiovascular system.13PubMed. The burden of musculoskeletal pain and the role of topical non-steroidal anti-inflammatory drugs (NSAIDs) in its treatment Topical capsaicin, derived from chili peppers, is another option some rheumatologists recommend for localized joint pain.
Joint injections are a mainstay of rheumatology practice. Corticosteroid injections delivered directly into a swollen joint can provide rapid, targeted relief with less systemic exposure than oral steroids. Hyaluronic acid injections are also used for osteoarthritic knees, though the evidence for their benefit is more debated. French rheumatology society recommendations, for example, include both corticosteroid and hyaluronic acid injections as options for knee osteoarthritis alongside topical NSAIDs and capsaicin.14PubMed. Recommendations of the French Society of Rheumatology on pharmacological treatment of knee osteoarthritis These procedures happen in the rheumatologist’s office and are often done during a routine visit.
NSAID Safety and the Monitoring That Goes With Prescribing
Because rheumatic disease patients often take NSAIDs for months or years, rheumatologists pay close attention to the safety profile of these drugs. Kidney function monitoring is standard. A consensus document from several specialty societies recommends that chronic rheumatic patients on NSAIDs have their kidney function assessed at least once a year, because these drugs can cause fluid retention, elevated creatinine, and in rare cases more serious renal problems. The risk is dose-dependent and accumulates over time.15Reumatología Clínica (English Edition). Safe Prescription Recommendations for Non Steroidal Anti-inflammatory Drugs: Consensus Document Elaborated by Nominated Experts of Three Scientific Associations (SER-SEC-AEG)
The reassuring finding from a prospective rheumatoid arthritis cohort is that for patients who start with reasonably healthy kidneys, chronic NSAID use does not appear to accelerate kidney decline meaningfully compared to people who never used them. The rate of kidney function loss was similar between NSAID users and non-users when baseline kidney function was above a certain threshold. NSAIDs were an independent predictor of faster decline only in patients who already had advanced renal impairment at the start.16Annals of the Rheumatic Diseases. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study This is one reason rheumatologists feel comfortable prescribing NSAIDs long-term for patients whose kidney function is stable, while being cautious with patients who have pre-existing kidney disease.
Cannabis and Cannabinoids in Rheumatology
Patients increasingly ask rheumatologists about medical cannabis for pain relief. A survey of patients with rheumatic conditions in the U.S. and Canada found that over half of American respondents and nearly 80% of Canadians reported past or current cannabis use, usually because other medications weren’t providing adequate symptom control. Compared to Canadians, fewer U.S. participants disclosed their cannabis use to their healthcare providers or asked for advice on how to use it.17PubMed Central. Medicinal Cannabis Use for Rheumatic Conditions in the US Versus Canada: Rationale for Use and Patient-Health Care Provider Interactions
The disconnect between patient interest and physician confidence is wide. A survey of rheumatologists found that over three-quarters lacked confidence in their knowledge of cannabinoid molecules, 70% had never prescribed or recommended any cannabinoid treatment, and only a quarter supported any use of herbal cannabis for rheumatology patients.18PubMed Central. Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints A separate Israeli survey echoed these findings, with about three-quarters of rheumatologists reporting they were not confident about writing a cannabis prescription, even though a similar proportion believed cannabinoids had some role in managing rheumatic disease.19PubMed Central. Attitudes of Israeli Rheumatologists to the Use of Medical Cannabis as Therapy for Rheumatic Disorders In practical terms, if you ask your rheumatologist about cannabis, you’re likely to get an honest admission that the evidence isn’t strong enough yet for them to recommend it formally, even if they’re open to the possibility that it helps some patients.
Non-Drug Approaches Rheumatologists Recommend
Pain management in rheumatology doesn’t stop at the prescription pad. Physical therapy and rehabilitation are integral parts of the treatment plan, and your rheumatologist will often refer you for these alongside medications. Treatment plans typically incorporate heat, cold, electrotherapy, and hydrotherapy for pain control, then progress to mobility work, posture training, and exercises aimed at restoring range of motion and muscle strength.20PubMed Central. Navigating Pain in Rheumatology: A Physiotherapy-Centric Review on Non-pharmacological Pain Management Strategies These non-pharmacological strategies are especially relevant for the residual pain that persists after disease activity is controlled, where adding more medication may not be the answer.
The approach taken can also depend on the patient’s age. A study examining how healthcare professionals manage pain in pediatric versus adult inflammatory and non-inflammatory musculoskeletal conditions found that biomedical management approaches, including medications, were more frequently selected for inflammatory conditions, while psychosocial approaches were prioritized for non-inflammatory pain.21Rheumatology Advances in Practice. Biopsychosocial pain assessment and management in paediatric inflammatory vs non-inflammatory musculoskeletal conditions: a vignette study In pediatric rheumatology, there’s generally more emphasis on integrating psychological support and coping strategies into the pain management plan from the start.
Access Disparities Shape What Gets Prescribed
Whether a rheumatologist prescribes pain medication, and what kind, can depend on factors beyond the disease itself. Evidence shows that racial and ethnic minorities, as well as people from lower socioeconomic backgrounds, experience delayed and reduced access to specialist care and lower use of advanced therapies. Structural barriers like insurance limitations and geographic gaps in the rheumatology workforce make these inequities worse.22Joint Bone Spine. Health equity and causes of disparities in rheumatological management If you can’t get to a rheumatologist in the first place, your pain management may end up handled entirely by a primary care physician who doesn’t have access to the same range of disease-modifying drugs and may rely more heavily on conventional painkillers as a result.
Rheumatologist shortages are a genuine problem in many areas, particularly in rural regions and in countries with fewer specialists per capita. Long wait times for appointments mean that by the time you see a rheumatologist, you may have already been prescribed pain medications by another provider. The rheumatologist then inherits a pain management regimen they may or may not agree with, adding another layer of complexity to an already difficult clinical conversation about what you’re taking and why.